
Quarterly report 2025-Q4
added 02-12-2026
Aethlon Medical Revenue 2011-2026 | AEMD
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Aethlon Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 574 K | 294 K | 659 K | 650 K | 230 K | 150 K | 392 K | 887 K | 762 K | 1.62 M | 1.23 M | 1.36 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.62 M | 150 K | 734 K |
Quarterly Revenue Aethlon Medical
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.1 K | 281 K | 264 K | - | 625 K | 625 K | - | - | 413 K | 413 K | - | 30 K | - | - | - | - | 74.8 K | - | - | - | - | 392 K | 4.64 K | - | - | - | - | - | 33.4 K | 479 K | 51.3 K | - | 76.3 K | 917 K | 840 K | - | 209 K | 826 K | 617 K | - | 958 K | 958 K | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 958 K | 4.64 K | 414 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
764 M | - | - | $ 1.05 B | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.6 | 4.2 % | $ 135 M | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 2.22 | 2.78 % | $ 1.35 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 11.47 | 3.33 % | $ 325 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 17.12 | 0.47 % | $ 402 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.57 | -5.8 % | $ 35.5 M | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 66.26 | 15.05 % | $ 3.61 B | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 11.26 | -2.34 % | $ 403 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.04 | -0.95 % | $ 17.6 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
64 M | - | 0.5 % | $ 219 M | ||
|
Myomo
MYO
|
40.9 M | $ 0.85 | -2.78 % | $ 35.6 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.55 | -5.6 % | $ 963 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Orthofix Medical
OFIX
|
822 M | $ 12.19 | -2.01 % | $ 483 M | ||
|
Insulet Corporation
PODD
|
2.71 B | - | - | $ 10.6 B | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 89.22 | -0.9 % | $ 12.1 B | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.4 | -0.83 % | $ 6.66 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 37.32 | 1.86 % | $ 1.16 B | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 45.7 | -5.42 % | $ 1.34 B | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 86.29 | 0.51 % | $ 3 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Stryker Corporation
SYK
|
7.17 B | $ 292.33 | -0.99 % | $ 112 B | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 83.2 | 0.35 % | $ 48.7 B | ||
|
TransMedics Group
TMDX
|
605 M | - | - | $ 2.48 B | ||
|
Tactile Systems Technology
TCMD
|
330 M | $ 25.3 | 5.2 % | $ 579 M | ||
|
Tandem Diabetes Care
TNDM
|
290 M | - | - | $ 1.23 B | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.39 | -1.73 % | $ 64.5 M |